ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
63 announcements
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma's subsidiary, Apitoria Pharma, incorporated a new wholly owned subsidiary named Avogent Lifesciences. The initial capital subscription for this pharmaceutical entity is Rs. 5 Crore.
Aurobindo Pharma's subsidiary, Lannett Company LLC, launched the generic version of Advair Diskus® in the US. This marks the company's first commercialized product from its inhalation pipeline.
Aurobindo Pharma held its 39th Annual General Meeting on August 27, 2026, to discuss financial statements, dividend, and director reappointments as per the AGM agenda.
Aurobindo Pharma reported the completion of a US FDA inspection at its subsidiary, Lannett Company LLC, which resulted in four procedural observations.
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd., received a US FDA Warning Letter for its Unit I manufacturing facility. The unit contributes approximately 2% to group revenue.
Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.
Aurobindo Pharma incorporated a new wholly owned subsidiary, 'Auropharm Overseas Limited'. The company subscribed to the subsidiary's share capital of Rs. 0.1 Crore.
Aurobindo Pharma approved the merger of its wholly-owned step-down subsidiaries, Eugia Steriles and Eugia SEZ, into its wholly-owned subsidiary, Eugia Pharma Specialities, to simplify the group structure.
Aurobindo reported strong Q1FY27 performance with revenue up 16.3% YoY to ₹9,150 Cr and PAT up 25.2% to ₹1,032 Cr, driven by US base business volume gains and European expansion.
Aurobindo Pharma Ltd reported revenue from operations of ₹9,150 Cr (+16.3% YoY) and net profit of ₹1,032 Cr (+25.2% YoY) for Q1 FY27.
Aurobindo Pharma dispatched letters to shareholders without registered email IDs. These letters provide a web link to the Integrated Annual Report 2025-26.
Aurobindo Pharma has submitted its Business Responsibility & Sustainability Report for the financial year 2025-26 to the stock exchanges.
Aurobindo Pharma Limited has submitted its Integrated Annual Report for FY 2025-26, alongside the notice for its 39th Annual General Meeting.
Aurobindo Pharma Limited has scheduled its 39th Annual General Meeting for August 27, 2026. The company also announced a closure of its Share Transfer Books for the AGM.
Aurobindo Pharma has scheduled a Board Meeting for August 5, 2026, to consider and approve its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
Aurobindo Pharma signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply generic alimatravir for 129 low- and middle-income countries.
Aurobindo Pharma's subsidiary, Apitoria, will acquire an 80% stake in A1 Biochem Group for USD 13.6 Million to bolster its contract research and manufacturing capabilities.
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received ANVISA (Brazil) approval for its biosimilars manufacturing facility in Hyderabad. This approval enables supply to Brazilian and Latin American markets.
Aurobindo Pharma Ltd created a new wholly‑owned subsidiary, PT Auro Pharm Indonesia, acquiring it for Rs.10.58 Crore cash. The step‑down subsidiary completes the incorporation on July 9 2026.
Aurobindo Pharma disclosed its subsidiary PT Aurogen Pharma Indonesia has created PT Auro Pharm Indonesia, subscribing cash of IDR 20 billion. The unit will manufacture in Indonesia.
Aurobindo Pharma USA Inc. completed the acquisition of Lannett Company LLC for ₹2,185 Crore. The deal adds Lannett's assets to Aurobindo’s portfolio.
Aurobindo Pharma USA Inc completed the acquisition of Lannett Company, making it a wholly‑owned subsidiary. The deal expands the group's capabilities in essential medicines.
US FDA completed an inspection at Auroactive Pharma, a wholly owned subsidiary. The inspection resulted in two observations to be responded to.
Aurobindo Pharma completed the acquisition of a 26% stake in Swarnaaskshu Solar Power for Rs.0.52 Crore. The deal secures solar power under Telangana's captive policy.
Aurobindo Pharma acquired a 26% stake in Swarnaakshu Solar Power. The investment is valued at Rs.10.40 Crore.
US FDA classified Aurobindo's subsidiary facility as OAI after an inspection. The company states no immediate financial impact but faces regulatory scrutiny.